Oncology Times - Ot Broadcasts From The Ipad Archives

Journalist Peter Goodwin gives OncTimes Talk a whirlwind review of the top 2022 breast cancer research as he reports live in person from the 2022 ESMO Berlin meeting. Featuring the following interviews with leading experts: 1. Patient-Reported Outcomes Support First-Line Pembrolizumab in TNBC: David Cescon, MD, PhD, Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Canada discusses analysis of patient-reported outcomes in the KEYNOTE-355 study in which adding pembrolizumab immunotherapy to chemotherapy did not impair health-related quality of life among patients with previously untreated, programmed death-ligand 1 (PD-L1) -positive advanced, triple negative breast cancer (TNBC). : 2. Combination Therapy to Convert Immunologically “Cold” Breast Tumors into “Hot” Ones: Alex De Caluwe, MD, Radiation Oncologist at the Institut Jules Bordet in Brussels, Belgium tells us about after his group’s findings from a “safety run-in” of the Neo-CheckRay study which raise hopes th